Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research - United States
doi 10.1158/2326-6066.cir-14-0053
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy
2019English

Response Assessment in Metastatic Melanoma Treated With Ipilimumab and Bevacizumab: CT Tumor Size and Density as Markers for Response and Outcome

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated With Ipilimumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Hospitalization and Emergency Department Utilization in Patients With Advanced Melanoma Receiving Pembrolizumab vs. Ipilimumab Plus Nivolumab in US Academic Centers

Journal of Medical Economics
Health Policy
2019English

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients With Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

PLoS ONE
Multidisciplinary
2012English

Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study

Frontiers in Immunology
AllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy